FACULTATEA DE MEDICINĂ ÎN LIMBA ENGLEZĂ FACULTY OF MEDICINE IN ENGLISH

CURRICULUM VITAE

Personal details:

Name, Surname: TILINCA Mariana Cornelia

Academic Title: Professor

Department: ME2 - clinical disciplines

Institutional e-mail: mariana.tilinca@umfst.ro

Areas of interest (maximum 5 domains):

Interdisciplinary clinical and paraclinical approach to metabolic disorders and associated pathology

Technologies used in diabetes management

Specialties: Internal Medicine, Diabetes, Nutrition and Metabolic Diseases

Competencies: General ultrasound

Certified: Health Services Management

Medical unit: County Emergency Clinical Hospital Târgu Mures, Clinical Department of Diabetes, Nutrition

and Metabolic Diseases

Research activity:

1. Research projects

- 1. Clinical-biological correlations in metabolic pathology and associated diseases
- 2. Clinical and paraclinical, inflammatory and metabolic status and the status of genetic polymorphisms, in relation to the development and evolution of obesity and type 2 diabetes in adults

2. Articles published in extenso

- Tilinca M.C., Antal C., Salcudean A., Abalașei B.L. et al., New directions in pharmacological treatment with SGLT-2 inhibitor molecules in the light of current guidelines for diabetes mellitus, heart failure and kidney disease, FARMACIA, 2023, 71(4), 686-69, IF: 1.6
- Mureşan A.V., Tomac A., Opriş D.R., et al., **Tilinca M.C**. *Inflammatory Markers Used as Predictors of Subclinical Atherosclerosis in Patients with Diabetic Polyneuropathy*, Life 2023, 13, 1861, IF: 3.2
- **Tilinca M.C.**, Gliga M., Varga A. *The pathophysiology and management of diabetic ketoacidosis in covid-19 patients: a literature review*, JCCM, 2022, 8(1): 6–13, IF:1.1
- **Tilinca M.C.,** Tiuca R.A., Tilea I., Varga A. *The SGLT-2 inhibitors in the personalized therapy in diabetes mellitus patients*, J. Pers. Med. 2021, 11, 1249, IF: 3.508
- **Tilinca M.C.,** Tiuca R.A., Niculas C., Varga A., Tilea I. *Future perspectives in diabesity approach:* semaglutide a glucagon-like peptide 1 receptor agonist, Exp Ther Med, 2021, 22: 1167, IF: 2.751
- **Tilinca M.C.**, Tiuca R.A., Burlacu A., Varga A. A 2021 update on the use of liraglutide in the modern treatment of 'diabesity': a narrative review, Medicina 2021, 57(7), 669, IF: 2.948

